6/13 (46%) in the placebo group (p<0.0001). Overall and transplant-free survival was similar between study groups; CHRSR was associated with significantly improved survival at Day 90 (p=0.0002). Adverse event (AE) incidence was similar for the 2 groups; serious AEs were reported in 59/97 (63.4%) subjects in the terlipressin group vs. 53/99 (55.8%) subjects in the placebo group. No new or unexpected AEs were reported. Summary: Terlipressin plus
albumin treatment is associated with improved renal function compared to albumin alone in patients with HRS-1; the improvement in renal function correlates with survival. Patients achieving CHRSR with terlipressin had a better outcome compared to those who responded to albumin alone. Conclusion: Terlipressin is effective in improving renal function in HRS-1. Disclosures: Thomas D. Boyer – Consulting: Ikaria; Grant/Research AP24534 Support: Abbvie, Gilead, Merck Arun J. Sanyal – Advisory Committees or Review Panels: Bristol Myers, Gilead, Abbott, Ikaria; Consulting: Salix, Immuron, Exhalenz, Nimbus, Genentech, Echo-sens, Takeda; Grant/Research Support: Salix, Genentech, Genfit, Intercept, Ikaria, Takeda, GalMed, Novartis, Gilead; Independent Contractor: UpToDate, Elsevier Florence Wong – Consulting:
Gore Inc; Grant/Research Support: Grifols R Todd Frederick – Advisory Committees or Review Panels: Vital Therapies; Consulting: Salix, Gilead, 17-AAG price Ocera, Hyperion John R. Lake – Advisory Committees or Review Panels: BMS; Consulting: Vital Therapies, Novartis, HepaHope; Grant/Research Support: Gilead, Salix, Ocera, Essai Jacqueline G. O’Leary – Consulting: Gilead, Jansen Daniel Ganger – Grant/Research Support: merck, gilead, Ocera Terry D. Box – Advisory Committees or Review Panels: Gilead, Genentech, Abb-Vie, Salix, Janssen; 上海皓元医药股份有限公司 Grant/Research Support: Gilead, Merck, BMS, AbbVie, Idenix, Salix, Conatus, Cumberland, Boehringer Ingelheim, Genfit, Vital Therapeutics, Sundise, ikaria; Speaking and Teaching: Gilead, Merck, Genentech, Salix Khurram Jamil – Employment: IKARIA; Stock Shareholder: IKARIA Stephen Chris Pappas – Consulting: Orphan Therapeutics, Abbvie “
“Aim: This study was conducted
to evaluate the efficacy and safety of radiofrequency ablation (RFA) therapy in elderly patients with hepatocellular carcinoma (HCC). Methods: Four hundred and sixty-one patients with naïve HCC, including 107 elderly (aged ≥75 years) patients, who were treated with RFA between 2000 and 2007, were enrolled. Baseline characteristics, survival/recurrence rates and complications after RFA were compared between elderly and non-elderly patients. Results: In the elderly group, the proportion of men, alcohol consumption, serum alanine aminotransferase and γ-glutamyl transpeptidase levels were significantly lower compared with those in the non-elderly group. There were no differences in Child–Pugh grade and tumor characteristics between the two groups.